# Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.

> **NCT06057194** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Maimónides Biomedical Research Institute of Córdoba** · enrollment: 90 (estimated)

## Conditions studied

- Infections, Cytomegalovirus

## Interventions

- **DRUG:** Letermovir 240 mg Oral Tablet

## Key facts

- **NCT ID:** NCT06057194
- **Lead sponsor:** Maimónides Biomedical Research Institute of Córdoba
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-10
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2023-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06057194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06057194, "Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06057194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*